vs
ANI PHARMACEUTICALS INC（ANIP）与UiPath, Inc.（PATH）财务数据对比。点击上方公司名可切换其他公司
UiPath, Inc.的季度营收约是ANI PHARMACEUTICALS INC的1.7倍（$411.1M vs $247.1M），UiPath, Inc.净利率更高（48.4% vs 11.1%，领先37.2%），ANI PHARMACEUTICALS INC同比增速更快（29.6% vs 15.9%），ANI PHARMACEUTICALS INC自由现金流更多（$29.1M vs $25.1M），过去两年ANI PHARMACEUTICALS INC的营收复合增速更高（34.1% vs 0.7%）
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
UiPath是一家全球化软件企业，专注于开发人工智能、智能自动化及流程编排类软件，其产品支持用户搭建与调度AI代理，实现复杂业务流程、工作流的自动化运行，助力各行业客户提升运营效率、降低人力成本。
ANIP vs PATH — 直观对比
营收规模更大
PATH
是对方的1.7倍
$247.1M
营收增速更快
ANIP
高出13.7%
15.9%
净利率更高
PATH
高出37.2%
11.1%
自由现金流更多
ANIP
多$4.0M
$25.1M
两年增速更快
ANIP
近两年复合增速
0.7%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $411.1M |
| 净利润 | $27.5M | $198.8M |
| 毛利率 | — | 83.3% |
| 营业利润率 | 14.1% | 3.2% |
| 净利率 | 11.1% | 48.4% |
| 营收同比 | 29.6% | 15.9% |
| 净利润同比 | 367.5% | 1966.2% |
| 每股收益（稀释后） | $1.14 | $0.37 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIPPATH
| Q4 25 | $247.1M | $411.1M | ||
| Q3 25 | $227.8M | $361.7M | ||
| Q2 25 | $211.4M | $356.6M | ||
| Q1 25 | $197.1M | $423.6M | ||
| Q4 24 | $190.6M | $354.7M | ||
| Q3 24 | $148.3M | $316.3M | ||
| Q2 24 | $138.0M | $335.1M | ||
| Q1 24 | $137.4M | $405.3M |
净利润ANIPPATH
| Q4 25 | $27.5M | $198.8M | ||
| Q3 25 | $26.6M | $1.6M | ||
| Q2 25 | $8.5M | $-22.6M | ||
| Q1 25 | $15.7M | $51.8M | ||
| Q4 24 | $-10.3M | $-10.7M | ||
| Q3 24 | $-24.2M | $-86.1M | ||
| Q2 24 | $-2.3M | $-28.7M | ||
| Q1 24 | $18.2M | $33.9M |
毛利率ANIPPATH
| Q4 25 | — | 83.3% | ||
| Q3 25 | — | 82.2% | ||
| Q2 25 | — | 82.1% | ||
| Q1 25 | — | 84.8% | ||
| Q4 24 | — | 82.0% | ||
| Q3 24 | — | 80.0% | ||
| Q2 24 | — | 83.5% | ||
| Q1 24 | — | 86.8% |
营业利润率ANIPPATH
| Q4 25 | 14.1% | 3.2% | ||
| Q3 25 | 15.9% | -5.6% | ||
| Q2 25 | 6.6% | -4.6% | ||
| Q1 25 | 13.3% | 7.9% | ||
| Q4 24 | -2.3% | -12.2% | ||
| Q3 24 | -13.8% | -32.7% | ||
| Q2 24 | 3.7% | -14.8% | ||
| Q1 24 | 14.8% | 3.7% |
净利率ANIPPATH
| Q4 25 | 11.1% | 48.4% | ||
| Q3 25 | 11.7% | 0.4% | ||
| Q2 25 | 4.0% | -6.3% | ||
| Q1 25 | 8.0% | 12.2% | ||
| Q4 24 | -5.4% | -3.0% | ||
| Q3 24 | -16.3% | -27.2% | ||
| Q2 24 | -1.7% | -8.6% | ||
| Q1 24 | 13.2% | 8.4% |
每股收益（稀释后）ANIPPATH
| Q4 25 | $1.14 | $0.37 | ||
| Q3 25 | $1.13 | $0.00 | ||
| Q2 25 | $0.36 | $-0.04 | ||
| Q1 25 | $0.69 | $0.09 | ||
| Q4 24 | $-0.45 | $-0.02 | ||
| Q3 24 | $-1.27 | $-0.15 | ||
| Q2 24 | $-0.14 | $-0.05 | ||
| Q1 24 | $0.82 | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $285.6M | $1.4B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $540.7M | $1.9B |
| 总资产 | $1.4B | $2.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ANIPPATH
| Q4 25 | $285.6M | $1.4B | ||
| Q3 25 | $262.6M | $1.4B | ||
| Q2 25 | $217.8M | $1.6B | ||
| Q1 25 | $149.8M | $1.6B | ||
| Q4 24 | $144.9M | $1.6B | ||
| Q3 24 | $145.0M | $1.7B | ||
| Q2 24 | $240.1M | $1.9B | ||
| Q1 24 | $228.6M | $1.9B |
股东权益ANIPPATH
| Q4 25 | $540.7M | $1.9B | ||
| Q3 25 | $505.8M | $1.7B | ||
| Q2 25 | $436.8M | $1.7B | ||
| Q1 25 | $418.6M | $1.8B | ||
| Q4 24 | $403.7M | $1.7B | ||
| Q3 24 | $405.9M | $1.8B | ||
| Q2 24 | $455.8M | $2.0B | ||
| Q1 24 | $452.0M | $2.0B |
总资产ANIPPATH
| Q4 25 | $1.4B | $2.9B | ||
| Q3 25 | $1.4B | $2.6B | ||
| Q2 25 | $1.3B | $2.6B | ||
| Q1 25 | $1.3B | $2.9B | ||
| Q4 24 | $1.3B | $2.7B | ||
| Q3 24 | $1.3B | $2.7B | ||
| Q2 24 | $920.8M | $2.8B | ||
| Q1 24 | $914.5M | $3.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | $28.3M |
| 自由现金流经营现金流 - 资本支出 | $29.1M | $25.1M |
| 自由现金流率自由现金流/营收 | 11.8% | 6.1% |
| 资本支出强度资本支出/营收 | 0.5% | 0.8% |
| 现金转化率经营现金流/净利润 | 1.10× | 0.14× |
| 过去12个月自由现金流最近4个季度 | $171.4M | — |
8季度趋势，按日历期对齐
经营现金流ANIPPATH
| Q4 25 | $30.4M | $28.3M | ||
| Q3 25 | $44.1M | $41.6M | ||
| Q2 25 | $75.8M | $119.0M | ||
| Q1 25 | $35.0M | $146.1M | ||
| Q4 24 | $15.9M | $28.1M | ||
| Q3 24 | $12.5M | $46.4M | ||
| Q2 24 | $17.4M | $100.0M | ||
| Q1 24 | $18.3M | $145.6M |
自由现金流ANIPPATH
| Q4 25 | $29.1M | $25.1M | ||
| Q3 25 | $38.0M | — | ||
| Q2 25 | $71.8M | $106.2M | ||
| Q1 25 | $32.5M | $138.7M | ||
| Q4 24 | $13.5M | $23.2M | ||
| Q3 24 | $7.7M | $45.0M | ||
| Q2 24 | $13.0M | $98.8M | ||
| Q1 24 | $13.7M | $141.8M |
自由现金流率ANIPPATH
| Q4 25 | 11.8% | 6.1% | ||
| Q3 25 | 16.7% | — | ||
| Q2 25 | 34.0% | 29.8% | ||
| Q1 25 | 16.5% | 32.7% | ||
| Q4 24 | 7.1% | 6.5% | ||
| Q3 24 | 5.2% | 14.2% | ||
| Q2 24 | 9.4% | 29.5% | ||
| Q1 24 | 10.0% | 35.0% |
资本支出强度ANIPPATH
| Q4 25 | 0.5% | 0.8% | ||
| Q3 25 | 2.7% | 0.0% | ||
| Q2 25 | 1.9% | 3.6% | ||
| Q1 25 | 1.3% | 1.7% | ||
| Q4 24 | 1.3% | 1.4% | ||
| Q3 24 | 3.2% | 0.4% | ||
| Q2 24 | 3.2% | 0.4% | ||
| Q1 24 | 3.3% | 0.9% |
现金转化率ANIPPATH
| Q4 25 | 1.10× | 0.14× | ||
| Q3 25 | 1.66× | 26.25× | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | 2.82× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | 4.29× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
PATH
| Subscription Services | $247.6M | 60% |
| License | $150.0M | 36% |
| Professional Services And Other | $13.5M | 3% |
